TPI Provides Further Updates on its GMOL Flagship Product

CHENGDU, China, July 6, 2012 /PRNewswire-Asia/ -- Tianyin
Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a
pharmaceutical company that specializes in patented
biopharmaceutical medicine, modernized traditional Chinese medicine
(mTCM), branded generics and active pharmaceutical ingredients
(API) today provided further updates on the business development of
TPI's flagship product: Gingko Mihuan Oral Liquid or GMOL
(H20013079), a prescription medicine that is used by physicians for
cardiovascular diseases such as stroke, coronary heart diseases,
angina, etc. The additional information regarding GMOL can also be
accessed at www.sfda.gov.cn, (Chinese version) or
http://baike.baidu.com/view/3029034.htm. GMOL was recently awarded
Essential Drug List (EDL) status in the City of Chongqing.
Chongqing, located in southwest China, with a population over 30
million and its status as the municipality directly under the
jurisdiction of the PRC Government along with other major cities
with the same status, Beijing, Tianjin and Shanghai which are
located in the east coastal area are regarded one of the most
attractive markets in pharmaceutical sales in China.

In April, TPI has announced the inclusion of GMOL as a
provincial supplementary Essential Drug Listed (EDL) product in
both Henan and Shandong provinces (with combined population of
approximately 200 million) which granted GMOL a full insurance
coverage (100% government reimbursement) for patients. GMOL
contributes approximately 50% of TPI's core product portfolio that
consists of GMOL, Apu Shuangxin Granules (Apu), Azithromycin
Tablets (Azi), Xuelian Chongcao (XLCC) and Qingre Jiedu Oral Liquid
(QR) and approximately 30% of TPI's total revenue.

Under the ongoing healthcare reform policy that favors the sale
of products that are listed in the EDL of China, the national and
provincial EDL listing could substantiate the market development of
these products.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company
that specializes in the development, manufacturing, marketing and
sales of patented biopharmaceutical, mTCM, branded generics and
API. TPI currently manufactures a comprehensive portfolio of 58
products, 24 of which are listed in the highly selective national
medicine reimbursement list, 7 are included in the national
essential drug list of China. TPI's pipeline targets various high
incidence healthcare indications. For more information about TPI,
please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this
press release are forward-looking statements that involve certain
risks and uncertainties including but not limited to risks
associated with the uncertainty of future financial results,
additional financing requirements, development of new products,
government approval processes, the impact of competitive products
or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission.

For more information, please visit:
http://www.tianyinpharma.com, or email ir@tpi.asia

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.